New imaging comparison could improve prostate cancer monitoring
NCT ID NCT06461689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor size and activity over time. The goal is to find the best way to monitor how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-PSMA-617 (a radioactive drug)
- What this could lead to
- If successful, this could help doctors choose the best imaging method to monitor treatment response in advanced prostate cancer.
- What could go wrong
- This is a small, completed study that only looks at imaging data, not patient outcomes. The results may not change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart resistant prostate cancer?
- Could fasting help the immune system fight prostate cancer?
- Could a new PET tracer reveal hidden prostate cancer activity?
- AI reads biopsies to predict cancer spread
- AI learns from 14,000 prostate scans to spot aggressive cancers
- Zapping just a few spots: new hope for patients with worsening metastatic cancer?